Blueprint Medicines to buy cancer drug startup with potential edge over Takeda, J&J targeted therapies


Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track to begin human testing in non-small cell lung cancer, and Blueprint believes the small molecule has advantages over new targeted therapies from Johnson & Johnson and Takeda Pharmaceutical.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.